Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences’ adjusted EPS topped consensus while losses narrowed year over year in the third fiscal quarter of 2026, based on preliminary results reported August 17, 2026. Adjusted EPS came in at -CAD 0.17, topping the -CAD 1.22 estimate by CAD 1.05, and improved +67.9% from -CAD 0.53 a year ago. Net income was a loss of about CAD 2.5 million, up +53.0% from a loss of CAD 5.2 million a year ago, while operating income was a loss of roughly CAD 11.7 million as the company continued funding development of its CNS drug candidates, including programs such as BMB-101 and BMB-201. Cash flow from operations was negative at around CAD 8.4 million for the quarter. For the next period, consensus calls for EPS of -CAD 1.07.